FDA Issues Safety Warnings on Boston Scientific Heart Devices Linked to Injuries and Fatalities
The FDA has issued safety warnings on Boston Scientific heart devices, alerting healthcare providers and patients about risks of device failure, injuries, and deaths associated with defibrillator wires and the Watchman stroke prevention device.
The U.S. Food and Drug Administration (FDA) has issued safety alerts concerning two Boston Scientific heart devices that have been associated with serious injuries and fatalities. The agency specifically highlighted issues with the company's Endotak Reliance defibrillator wires and the Watchman device used for stroke prevention.
For the defibrillators, the FDA reports that the wires can develop calcification over time, which may lead to device failure in delivering life-saving shocks during cardiac emergencies. This problem has resulted in 386 serious injuries and 16 deaths as reported by Boston Scientific up to July 24. Among the fatalities, ten were attributed to device malfunction, while others involved surgical removal procedures or were deemed unrelated.
These wires were distributed between 2002 and 2021 and are no longer available. Patients with these devices might require replacement, though medical professionals should consider the risks associated with surgical removal.
Separately, the FDA also addressed concerns related to Boston Scientific's Watchman device, which is implanted in the heart's left atrium to reduce stroke risk in patients with atrial fibrillation. The company recently updated its implantation instructions after discovering an increased risk of bloodstream blockages during the procedure, especially depending on anesthesia levels. As of July 30, there have been 120 serious injuries and 17 deaths linked to issues with the Watchman device. A company investigation found that these safety concerns are not related to the design or manufacturing defects.
Boston Scientific's heart-related products are a significant part of its revenue, comprising about two-thirds of its $5 billion quarterly income. The company has alerted healthcare providers to these issues and emphasized careful patient selection and procedural considerations.
Shares of Boston Scientific saw a decrease of approximately 1.8%, closing at $102.95 following the news. Patients and clinicians are advised to stay informed about these safety concerns and consult healthcare professionals for appropriate management.
source: https://medicalxpress.com/news/2025-08-fda-flags-problems-boston-scientific.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Study Uncovers Three Main Causes of Dental Anxiety Onset
A groundbreaking study identifies the three primary causes of dental anxiety, highlighting the importance of targeted interventions to improve patient experiences and oral health outcomes.
Innovative Approach to Preventing Breast Cancer Recurrence Using Dormant Cell Targeting
A novel clinical trial demonstrates that detecting and targeting dormant breast cancer cells using existing drugs can prevent relapse and improve long-term survival outcomes.
Innovative Antibiotic Developed for IBD Using AI Prediction and Discovery
Scientists at McMaster and MIT have discovered a targeted antibiotic for IBD using AI to predict how the drug works, accelerating development and enhancing precision medicine.
Innovative Strategy Empowers Pediatricians to Promote Early Peanut Introduction for Allergy Prevention
A new clinical trial highlights how targeted education and decision-support tools for pediatricians can improve early peanut introduction practices, helping reduce the incidence of peanut allergies in children.